Book chapter
135 - Neuroendocrine Tumor Syndromes
DeGroot's Endocrinology, pp.2274-2290
Elsevier Inc, Eighth Edition
2023
DOI: 10.1016/B978-0-323-69412-4.00135-4
Abstract
Neuroendocrine neoplasms arise from a diversity of organs and are known for their ability to secrete peptide hormones and bioactive amines. The majority of neuroendocrine tumors are indolent, although metastatic, at diagnosis. Clinical syndromes reflective of the physiologic function of the secreted substance result in approximately 10% to 30% of cases. Appropriate workup includes a thorough history and physical exam, imaging, and biopsy. Diagnostic laboratory studies are limited to confirmation of a clinical syndrome. Otherwise, neuroendocrine biomarkers are best used to monitor for progression and recurrence. Surgical resection is the treatment of choice for localized tumors, and in many cases where the primary and all visible metastases can be removed. Tumor control, and in some cases cytoreduction, may also be achieved via a number of systemic therapies when the extent of disease or patient condition precludes operation. Disease control is difficult and best managed by multidisciplinary teams at high-volume institutions.
Details
- Title: Subtitle
- 135 - Neuroendocrine Tumor Syndromes
- Creators
- Jessica E. MaxwellJoseph S. DillonDaniel M. Halperin
- Resource Type
- Book chapter
- Publication Details
- DeGroot's Endocrinology, pp.2274-2290
- Edition
- Eighth Edition
- DOI
- 10.1016/B978-0-323-69412-4.00135-4
- Publisher
- Elsevier Inc; Philadelphia, PA
- Language
- English
- Date published
- 2023
- Academic Unit
- Fraternal Order of Eagles Diabetes Research Center; Endocrinology and Metabolism; Internal Medicine
- Record Identifier
- 9984927215102771
Metrics
1 Record Views